Medication stability and
the nervous system

Two kinds of stability

When people talk about being stable on psychiatric medication, they are describing something real — a reduction in the intensity and frequency of distressing experiences, an increased sense of being able to function, a floor beneath which things do not fall. This is not nothing. For many people, medication has been a lifeline at a difficult point in their lives, and that deserves acknowledgement.

But there is an important distinction that is rarely made clearly: the stability that medication provides is chemical stability — a form of external regulation, maintained as long as the medication is taken at the appropriate dose. It is not the same as inner stability — the nervous system's own capacity to regulate itself, manage stress, and return to equilibrium after disturbance.

These two forms of stability are not mutually exclusive. They can coexist. But they are also not interchangeable — and understanding the difference is important for anyone considering whether and how to change their medication.

What psychiatric medication does to the nervous system

Psychiatric medications — antidepressants, antipsychotics, anxiolytics, mood stabilisers — act on the nervous system by modifying neurotransmitter activity. SSRIs and SNRIs increase serotonin or noradrenaline availability at synapses. Benzodiazepines enhance GABA, the brain's primary inhibitory neurotransmitter. Antipsychotics block dopamine and serotonin receptors. Each mechanism is different, but the common thread is that all of these medications alter the way the nervous system operates.

In the short term, these alterations can produce significant relief — reduced anxiety, lifted mood, quietened psychosis, stabilised sleep. The nervous system, running in a dysregulated or distressed state, is brought to a calmer operating point by the medication's effect.

Over time, however, the nervous system does what all adaptive biological systems do: it adjusts to the new conditions. It compensates for the medication's presence by modifying receptor sensitivity, altering neurotransmitter production, and recalibrating its own regulatory patterns. The result is that the nervous system comes to function in a way that is, in a sense, built around the medication. The medication is no longer simply modifying the system — it has become part of how the system operates.

What this means for deprescribing

This process of neuroadaptation is clinically significant for anyone considering medication reduction. When the medication is reduced or removed, the nervous system is suddenly operating in conditions it has not experienced — sometimes in years or decades — and it needs time to recalibrate. This is the physiological basis of withdrawal: not a moral failing, not a sign of weakness, not evidence that the medication is necessary forever. It is a biological adjustment.

The pace at which the nervous system can make this adjustment depends on several factors: how long the medication has been present, at what dose, and how much the system has adapted. More adaptation requires more time and a more gradual pace of reduction. This is why hyperbolic tapering — making proportionally smaller reductions as the dose falls — is not an arbitrary preference but a pharmacologically grounded approach that matches the pace of reduction to the nervous system's actual capacity to adjust.

Chemical stability versus inner stability

One of the most important questions in deprescribing is whether a person's stability, during the period of reduction and afterwards, is primarily coming from the medication or primarily coming from within. This is not always easy to know — partly because the two are intertwined after years of medication use, and partly because the original condition that prompted the prescription may have changed significantly since then.

Chemical stability is real and it is valuable. But it is externally dependent — on continued access to the medication, on consistent dosing, on the absence of formulation changes or supply disruptions. It does not grow. It does not deepen. It does not give the nervous system an increasing capacity to manage its own regulation over time.

Inner stability is different. It develops through experience — through learning to tolerate and interpret the nervous system's signals rather than fearing them, through building resources and relationships that support regulation, through processing the underlying experiences that may have driven the original dysregulation. It is slower to develop than chemical stability, but it is not externally dependent. It belongs to the person rather than to the prescription.

This distinction matters in deprescribing because the goal is not simply to remove the medication — it is to reach a point where inner stability is sufficient to sustain the person without it. That point is different for everyone, and in some cases it may never be reached. But for many people who have been on medication for years, the presence of inner stability is underestimated, because it has been quietly developing alongside the medication without being noticed or named.

The nervous system as the guide

One of the foundational principles of safe deprescribing is that the nervous system itself is the guide for the pace and process of reduction. This is not a metaphor — it is a practical clinical principle.

When a reduction produces significant symptoms, the nervous system is communicating that the pace was too fast for its current capacity. The appropriate response is to slow down, hold the current dose, and wait for the system to settle — not to push through, and not to interpret the symptoms as evidence that reduction is impossible. Symptoms are information, not verdicts.

When the nervous system is stable after a reduction — when the person reports no significant change in their functioning or wellbeing — the pace can continue. The nervous system has absorbed the change and found a new equilibrium. This equilibrium-seeking capacity is one of the most important things to understand about the nervous system: it is not fixed or fragile. It is adaptive and resilient, provided it is not asked to adapt too quickly.

Supporting the nervous system during reduction

Deprescribing does not happen in isolation from the rest of a person's life. The nervous system's capacity to tolerate and integrate the changes that medication reduction requires is affected by everything that person is experiencing — their sleep, their relationships, their relationship with their own body, their sense of safety in the world.

This is why our approach to deprescribing is not purely pharmacological. Alongside the clinical management of the taper, we pay close attention to the conditions that support nervous system stability — and where those conditions are absent or fragile, we work on them before or alongside the reduction rather than assuming they will look after themselves.

This does not mean that someone needs to have resolved all of their difficulties before they can consider reducing medication. It means that the process of deprescribing is most likely to be safe and sustainable when it is understood as a whole-person process, not simply a dose-reduction exercise.